Hyqvia (Human Normal Immunoglobulin, Hyaluronidase (Human Recombinant))

Hyqvia is used in the management of primary immunodeficiency disorders that require immunoglobulin replacement therapy.

• Common Variable Immunodeficiency (CVID): maintains protective IgG levels to reduce infection frequency.
• X‑linked Agammaglobulinemia (XLA): provides necessary IgG antibodies for immune defense.
• Severe Combined Immunodeficiency (post‑transplant or after conditioning): supports immune reconstitution and infection prophylaxis.
• Hyper IgM Syndrome: supplies IgG to compensate for class‑switch deficiency.
• Primary Antibody Deficiency after hematopoietic stem cell transplantation: sustains immunity during engraftment.

• Hyqvia combines human normal immunoglobulin with recombinant human hyaluronidase. The hyaluronidase temporarily depolymerizes hyaluronan in the subcutaneous extracellular matrix, increasing tissue permeability and allowing a larger volume of immunoglobulin to be dispersed and absorbed rapidly. The infused IgG then circulates, providing passive antibodies that replace the deficient endogenous IgG in patients with primary immunodeficiency and contributes to long‑term protection against bacterial and viral pathogens.

Hyqvia may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Infusion site erythema or swelling: mild local reaction at the injection site
• Headache: transient discomfort often resolving without treatment
• Fatigue: general tiredness that may improve after rest
• Nausea: mild gastrointestinal upset
• Low‑grade fever: temperature rise below 38.5 °C
• Myalgia: muscle aches commonly reported

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions: potentially life‑threatening hypersensitivity
• Thromboembolic events (e.g., deep vein thrombosis): blood clot formation requiring urgent care
• Acute renal dysfunction or failure: sudden loss of kidney function
• Hemolysis: destruction of red blood cells
• Aseptic meningitis: inflammation of meninges without infection
• Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome): serious skin involvement

Before initiating Hyqvia therapy, several precautionary measures should be considered to ensure patient safety.

• Assess renal function: evaluate baseline serum creatinine and monitor periodically
• Screen for IgA deficiency: patients with anti‑IgA antibodies have higher anaphylaxis risk
• Review thrombotic history: avoid use in individuals with recent clotting events
• Monitor blood pressure: uncontrolled hypertension may be exacerbated by infusion volume
• Caution with live vaccines: immunoglobulin may reduce vaccine efficacy
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Hyqvia can interact with other medicines; awareness of these interactions helps manage therapy safely.

Major Interactions (Avoid)

• Concurrent immunoglobulin products: risk of IgG overload and increased viscosity
• Live vaccines: may result in reduced vaccine effectiveness
• Nephrotoxic agents (e.g., aminoglycosides): heightened risk of renal impairment

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., rituximab): may alter response to therapy
• Corticosteroids: can mask infusion‑related reactions
• Anticoagulants: potential for altered bleeding risk due to volume load